IMI at BIO 2016Start Date 06/06/2016 End Date 09/06/2016
IMI took part in the 2016 edition of the BIO International Convention in San Francisco, US on 6-9 June 2016.
Workshop on novel anti-infectives
IMI teamed up with its ENABLE project and the Wellcome Trust-funded Community For Open Antimicrobial Drug Discovery (CO-ADD) to organise a workshop dedicated to novel antibiotics and antimicrobial resistance (AMR) innovation. The workshop brought together around 200 people from the scientific, finance and business communities to network around promising antibiotic products and technologies. Specifically, it showcased global research programmes supporting the development of novel anti-infectives as well as 10 innovative small companies from around the world that are pioneers in the development of new antibiotics. A panel of judges picked Bioversys as the best presentation, while EpiBiome won the public vote.
- The Innovative Medicines Initiative New Drugs for Bad Bugs programme
Pierre Meulien, IMI
- CO-ADD - Open-access antimicrobial drug discovery
Matt Cooper, CO-ADD
- The ENABLE project - Funding and supporting European antibacterial drug discovery against gram negative pathogens
Claire Skentelbery, ENABLE project
- Andrew Hopkins, VICAL, United States
- Stefania Mariani, Diatheva SrL, Italy
- Marc Lemmonier, Antabio, France
- Deborah O’Neil, Novabiotics, United Kingdom
- Nick Conley, Epibiome, United States- Best presentation (public vote)
- Mark Craighead, RedX, United Kingdom
- Marc Gitzinger, Bioversys, Switzerland - Best presentation (judges' vote)
- Michael Graz, Neem Biotech, United Kingdom
- Jonathan Butcher, Polyphor, Switzerland
- Thomas Kapsner, Morphochem AG, Germany
IMI session ‘Revolutionizing Clinical Trials for Alzheimer’s: An International Perspective on Adaptive Clinical Trials’
Over 150 people attended a session organised by IMI in the brain health track of the BIO educational programme. Despite decades of research, there is still neither treatment nor cure for Alzheimer’s disease and success in clinical trials remains elusive. Pioneering projects on both sides of the Atlantic are working together to turn this situation around by running adaptive clinical trials – a first in Alzheimer’s research. In this session, leading dementia experts, including from IMI's EPAD project, shared their experiences and discussed how best to overcome the challenges to delivering successful clinical trials for much-needed Alzheimer’s treatments.
- Welcome and introduction
Pierre Meulien | Executive Director, Innovative Medicines Initiative
- The need for collaboration and trial innovation in Alzheimer's disease
Paul Stoffels | Chief Scientific Officer, Johnson & Johnson
- Changing the game in Alzheimer's disease - public-private partnerships for effective clinical trials
Simon Lovestone | Professor of translational neuroscience, University of Oxford
- Perspective from the Alzheimer's Association
Heather Snyder | Senior Director, Medical & Scientific Relations, Alzheimer’s Association
Session ‘Bridging the Gap: Alignment of Global Antibiotic R&D Partnerships’
IMI Executive Director Pierre Meulien was a speaker in this session on the critical need for global alignment in the anti-infective development chain.
- Download Pierre Meulien's presentation
IMI at the exhibition
IMI was also present at the European Commission’s booth at the BIO Exhibition.
The BIO International Convention (BIO) attracts over 15 000 biotechnology and pharma leaders who come together for a week of intensive networking and partnering opportunities. The event features a strong educational programme as well as an expansive exhibition floor.
- Event website: http://convention.bio.org/
- Twitter: #BIO2016